Precigen provides pipeline and corporate updates at the 41st annual j.p. morgan healthcare conference

–  company achieved significant progress for its clinical pipeline in 2022  – –  precigen to host r&d day virtual event on january 24, 2023, at 4:30 pm et to share safety and efficacy data from the phase 1 dose escalation and expansion cohorts of prgn-2012 adenoverse™ immunotherapy in recurrent respiratory papillomatosis (rrp) – germantown, md. , jan. 11, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 41st annual j.p.
PGEN Ratings Summary
PGEN Quant Ranking